Methylphenidate (MPD) is the most widely used drug in the treatment of attention-deficit hyperactivity disorder (ADHD), the symptoms of which can persist into adolescence and adulthood. The cooccurrence of other psychiatric disorders, such as anxiety and alcoholism, in adults with ADHD is very common, but its etiology remains largely unknown. This study examined the effects of chronic MPD treatment during adolescence on emotional and consummatory behaviors in adult spontaneously hypertensive rats (SHRs), often proposed as an animal model of ADHD. Adolescent SHRs of both sexes were given chronic treatment with MPD (2 mg/kg intraperitoneally; twice daily for 16 days) or vehicle and were subsequently tested in adulthood. The tests used were the open-field and the elevated plus-maze, thought to measure locomotor and emotionality-related behaviors, and a protocol of ethanol consumption. MPD elicited anxious-like behavior in the open-field (but not in the elevated plus-maze) regardless of sex, and enhanced ethanol intake in females. These findings suggest that MPD treatment during adolescence induces persistent changes on emotionality and ethanol consumption in SHRs, but these effects depend on the sex and behavioral test used. Potential clinical implications of these findings are discussed.
Introduction
Attention-deficit hyperactivity disorder (ADHD), one of the most common childhood neuropsychiatric disorders, includes behavioral and cognitive symptoms, such as inattention and impulsivity/hyperactivity. In more than 50% of children with ADHD, the symptoms persist into adolescence and adulthood (Murphy and Barkley, 1996; Goldman et al., 1998) . It is now estimated that 4% of adults suffer from ADHD (Faraone and Biederman, 2005; Kessler et al., 2006) . Moreover, there has been an increasing recognition of the cooccurrence of ADHD with other psychiatric disorders, notably mood disorders, anxiety disorders and drug addiction (Biederman et al., 1994; Biederman, 2005; Wilens et al., 2005; Fischer et al., 2007) . The presence of more than one cooccurring psychiatric disorder with ADHD is also common. For example, individuals with ADHD and substance use disorders present higher rates of anxiety disorders than individuals with either ADHD or substance use disorder alone (Wilens et al., 2005) . The identification of the neurobiological mechanisms underlying ADHD with comorbidity is necessary as this condition may further complicate the diagnosis and treatment of the individuals (Wilens et al., 2005) .
Methylphenidate (MPD), also known as Ritalin, is the most widely used drug in the treatment of ADHD (see, for review, Leonard et al., 2004) . MPD is a piperidine derivative known to block dopamine (DA) uptake by brain DA transporters (Gatley et al., 1996) in a similar way to potent psychostimulants such as cocaine and amphetamine. MPD is very effective in treating ADHD; however, its adverse effects remain controversial. Although there is evidence showing that therapeutic treatment of ADHD with MPD increases the risk of drug addiction (Lambert and Hartsough, 1998) , other studies have actually reported that this treatment reduces the risk of substance abuse disorders (Biederman et al., 1999) . The role of MPD treatment in other cooccurring psychiatric disorders remains to be established. Brandon et al. (2001) have reported that MPD treatment of rats from postnatal day (PD) 35 to 42 enhanced psychomotor responses to cocaine and facilitated acquisition of intravenous cocaine self-administration. Similarly, Crawford et al. (2007) have shown that rats treated with MPD in an earlier period (PD11-20) displayed increased rewarding effects for morphine or sucrose. These findings suggest that MPD treatment makes the reward system more sensitive to appetitive stimuli. In contrast, other studies have reported that rats given MPD early in life showed reduced rewarding effects of cocaine in place conditioning (Andersen et al., 2002; Carlezon et al., 2003; Adriani et al., 2006) and intracranial self-administration (Mague et al., 2005) tests. In addition, MPD-treated rats (PD20-35) were shown to be less sensitive to natural rewards (e.g. sucrose, novelty and sexual behavior), more sensitive to stressful situations and more prone to anxiety and depressive-like behaviors compared with vehicle-treated animals (Bolaños et al., 2003; Carlezon et al., 2003) . Despite some inconsistencies between studies, presumably caused by methodological differences, it is clear that MPD treatment during development causes long-lasting neurobiological effects in rodents, some of which are related to reward and emotionality (Andersen et al., 2002; Adriani et al., 2006; Grund et al., 2006) .
It should be noted, however, that the effects of MPD reported in the aforementioned studies have, so far, been seen only in 'normal' animals (e.g. Sprague-Dawley, Wistar rats), whose behavioral reactions could be considered as adequate from the adaptive point of view. Hence, the effects of MPD in animal models of ADHD, which might represent a better model of psychopathological states in humans, remain to be determined. One of the most extensively evaluated animal models of ADHD is the spontaneously hypertensive rat (SHR). On comparison with their normotensive controls (WistarKyoto) and with some other rat strains, SHRs show a sustained attention deficit hyperactivity, in some situations and motor impulsiveness, thus featuring the main symptoms of ADHD Sagvolden et al., 2005) . Moreover, they are novelty-seekers and risk-takers, and show increased sensitivity to cocaine and drink large amounts of ethanol (Da Silva et al., 2005; Vendruscolo et al., 2006; Pamplona et al., 2007) . Nevertheless, the validity of the SHR strain as a model of ADHD has been recently challenged (Van den Bergh et al., 2006; Alsop, 2007) .
Although there are studies reporting the effects of MPD in SHRs ( Van den Bergh et al., 2006) , to our knowledge, only one study has evaluated some enduring effects of chronic MPD treatment in this strain. Augustyniak et al. (2006) have reported that SHRs given MPD during adolescence (PD35-44) showed reduced cocaine placepreference in adulthood.
In view of the limited number of studies and of the lack of agreement among them concerning the long-lasting effects of this widely used psychopharmacological therapy, the objective of this study was to evaluate the consequences of repeated MPD treatment of pre/ periadolescent SHRs in terms of emotional and consummatory behaviors in adulthood. For this purpose, SHRs were given two daily injections of MPD (2 mg/kg) for 16 consecutive days. This dose of MPD and treatment schedule, which have been reported to produce plasma and brain levels of MPD that approximate clinically relevant doses administered to ADHD children, were chosen on the basis of earlier studies (Andersen et al., 2002; Bolaños et al., 2003) . The animals were treated from PD23 to PD38, which has been proposed to be a period equivalent to human childhood/adolescence (Spear, 2000; Andersen, 2003) . Animals of both sexes were included in the study because the effects of MPD have rarely been studied in females (Torres-Reveron and Dow-Edwards, 2005; Crawford et al., 2007) .
Methods

Subjects and chronic treatment with methylphenidate
Pregnant female SHRs bred from our own colonies (see, for details, Izídio et al., 2005) were individually housed in plastic cages. The day of birth was considered as PD zero. On each day from PD23 to PD38, male and female pups were weighed and given an intraperitoneal injection of either saline vehicle (SAL, 0.9% NaCl) or MPD (Ritalin, Novartis, Taboão da Serra, Brazil; 2.0 mg/kg dissolved in SAL) twice daily (4 h apart, first injection at 09.00 h) for 16 consecutive days, in an injection volume of 5 ml/kg. Owing to the small size of the rat pups, this volume of injection allowed us to control the amount of drug injected better and thus increase the precision of the treatment. The average ( ± SEM) weight of the animals (SAL-treated Â MPD-treated rats, respectively) was 35.7 ± 1.4 Â 37.3 ± 1.3 g for males on the first day of treatment, 93.5 ± 2.5 Â 93.5 ± 2.6 g for males on the last day of treatment, 31.7 ± 1.2 Â 32.2 ± 0.7 g for females on the first day of treatment and 79.4 ± 1.8 Â 79.1 ± 1.4 g for females on the last day of treatment (P > 0.05 for all comparisons; n = 10-12 per group). Rat pups were weaned and separated into groups of five or six (same sex) per cage on PD28. The behavioral tests were conducted in early adulthood, 4 weeks after the end of the treatment, at 9-10 weeks of age. The rats were maintained with food and water freely available under a 12-h light/dark cycle (lights on at 07.00 h) at 22 ± 21C. This study was performed in accordance with the guidelines of 'Guiding principles in the care and use of animals' (DHEW Publications, National Institutes of Health, 80-23).
Behavioral tests
The animals were submitted successively to a battery of behavioral tests with at least 3-day intervals between tests. All tests were carried out between 14.00 and 18.00 h. The battery of tests is described below in the order of testing.
Open-field
The apparatus consisted of a large arena made of wood, covered with white Formica and surrounded by white walls that were 40-cm high. The floor of 100 Â100 cm was divided by black lines into 25 squares (20 Â 20 cm). The illumination in the center of the apparatus was 8 lux. Each rat was placed in the center of the open-field (OF) and the number of peripheral squares (adjacent to the walls) crossed (peripheral locomotion), of central squares (away from the walls) crossed (central locomotion) and of fecal boli dropped was registered for 5 min.
Elevated plus-maze
The apparatus was made of wood covered with a layer of black Formica and had four elevated arms (52 cm above the floor) 50-cm long and 10-cm wide. The arms were arranged in a cross-like arrangement, with two opposite arms being enclosed (by 40-cm high opaque walls) and two being open but with a lip (1-mm thick and 5-mm high). A central platform at their intersection (10 Â 13.5 cm) gave access to any of the four arms. The central platform was under 8 lux of illumination. Each rat was placed on the central platform facing an open arm and the following behaviors were registered for 5 min: the number of entries and the time spent (with all four paws) inside each type of arm. The floors of both OF and elevated plus-maze (EPM) apparatuses were cleaned with a sponge wetted with 10% ethanol and dried with paper towel between rats. The behavior of each animal was recorded via a video camera positioned above the apparatuses and monitored in another room via a closed circuit TV camera. After behavioral assessments in both OF and EPM tests, female rats were subjected to vaginal smears to determine the phase of the estrous cycle (Hoar and Hickman, 1975) . Such a control showed that the cycles of female rats grouped by treatment were evenly distributed among all the stages, thus suggesting that any behavioral effects should be owing to the drug and not to the clustering of female rats in one stage of the estrous cycle.
Saccharine and quinine consumption
A standardized testing procedure for saccharine, quinine and ethanol consumption was used (Vendruscolo et al., 2006) , with some modification. After a 5-day habituation period in individual plastic cages the animals were given a free choice between two bottles containing either saccharine solution (7.5 mmol/l as the sodium salt, Vetec Laboratories, Rio de Janeiro, Brazil) or water, on 2 consecutive days. Each day the two bottles were weighed and refilled and their position was changed, within the same 2-h interval. For quinine consumption, the test followed the same protocol as for saccharine, with a 2 mmol/l quinine (ICN Biomedicals, Solon, Ohio, USA) solution being used. The data were expressed as an index that measures the fluid ingestion when saccharine (or quinine) was available according to the following formula: volume of saccharine (or quinine) plus the volume of water consumed in the same period divided by the normal volume of water consumed in 24 h (measured during the preceding day), expressed as a percentage.
Two-choice ethanol
The animals were given a choice between water and 10% ethanol (v/v; Vetec). The bottles were weighed (refilled if necessary) every 2 days for 10 two-day periods (i.e. over 20 days). Data are expressed in gram of ethanol/day/kg of body weight. Between saccharine, quinine and ethanol conditions, water was given as the sole source of drinking fluid for 2 days. The body weight of the rats was recorded at least once a week.
Statistical analysis
The OF, EPM, saccharine and quinine data were analyzed using a two-way analysis of variance (ANOVA) for sex and treatment factors. The ethanol consumption data were analyzed using a three-way ANOVA (sex, treatment and time) with repeated measures on the time factor (10 twoday blocks). The Newman-Keuls test was used for posthoc comparisons when appropriate. The accepted level of significance for all tests was P < 0.05. Data are presented in the text and figures as means and SEM.
Results
Open-field
The results for central and peripheral locomotion in the OF are illustrated in Fig. 1 . For central locomotion, the two-way ANOVA revealed significant overall sex [F(1,41) = 27.9; P < 0.001] and treatment [F(1,41) = 4.7; P < 0.05] effects. These data indicated that male rats crossed fewer squares in the central aversive area of the OF than female rats and, more importantly, that MPD-treated rats made fewer crossings in the center of the OF than SAL-treated rats. No significant interaction was found between factors. For peripheral locomotion, only a significant sex effect was observed [F(1,41) = 6.8; P < 0.02], with female rats being more active than male rats. Defecation was almost absent so that no clear effect could be observed. Figure 2 illustrates the change in fluid intake induced by the availability of a saccharine (7.5 mmol/l) or quinine (2 mmol/l) solution in free choice with water for 2 consecutive days. For saccharine consumption, the twoway ANOVA revealed only a sex effect [F(1,43) = 26.2; P < 0.001] with females showing a greater increase in fluid consumption than males. No differences were found for quinine consumption.
Two-choice ethanol
The results of two-choice ethanol drinking are presented in Fig. 3 . For ethanol intake, the three-way ANOVA for repeated measures revealed a significant interaction between sex and treatment [F(1,35) = 4.1; P < 0.05], and between sex and time [F(9,315) = 4.3; P < 0.001]. The post-hoc comparisons indicated that females treated with MPD during development showed higher ethanol intake than SAL-treated females (P < 0.02). Regarding ethanol preference, the three-way ANOVA revealed only a significant effect of sex [F(1,39) = 63.8; P < 0.001] and time [F(9,351) = 10.2; P < 0.001], with females showing higher ethanol preference than males.
Discussion
ADHD treatment in humans is basically carried out with the psychostimulant MPD (Leonard et al., 2004) , which has proven to be a very effective drug against the main symptoms of the disorder. Little is known, however, about the enduring adverse effects of chronic MPD treatment. The vast majority of adults with ADHD present at least one lifetime psychiatric comorbidity (Biederman et al., 1994; Biederman, 2005; Wilens et al., 2005; Fischer et al., 2007) . Whether or not MPD treatment during childhood/adolescence contributes to the high rates of psychiatric comorbidity in ADHD remains to be established. This study reports that chronic MPD treatment (2 mg/kg intraperitoneally; twice daily 75.6 ± 11.2 9.4 ± 0.7 9.6 ± 0.6 N = 10-12 per group. Overall sex effects were significant for both variables (ANOVA, P < 0.01). ANOVA, analysis of variance; MPD, methylphenidate; SHRs, spontaneously hypertensive rats. Relative fluid consumption when saccharine (7.5 mmol/l) or quinine (2 mmol/l) solutions were available in free choice with water (mean of two consecutive days) of male and female SHRs treated during pre/ periadolescence (PD23-38) with MPD (2 mg/kg intraperitoneally, twice daily for 16 consecutive days) or SAL. Data are expressed as an index that consists of the volume of fluid ingested when saccharine or quinine was available to the animal in relation to the normal water consumption (measured in the preceding days), expressed as percentage. Bars and vertical lines represent the means and SEM of animals grouped by sex and treatment; n = 11-12 per group. + + P < 0.01 for effect of sex. MPD, methylphenidate; PD, postnatal day; SHRs, spontaneously hypertensive rats.
for 16 days) of pre/periadolescent (PD23-38) SHRs led adult rats, regardless of sex, to display increased anxious-like behavior. In addition, this treatment increased ethanol drinking in females.
MPD-treated rats made fewer crossings in the central, but not peripheral, area of the OF when compared to SAL-treated rats. This finding suggests that MPD treatment during adolescence elicited anxious-like behavior in adult rats. The OF was originally developed as a test of emotionality (Hall, 1936) . In this large novel arena, rodents tend to avoid the center and concentrate their ambulation in the peripheral area. Thus, in the OF, central locomotion is generally considered as an index of experimental anxiety, whereas peripheral locomotion is thought to represent general locomotion (Ramos and Mormède, 1998; Prut and Belzung, 2003) . This emotional influence of MPD, however, was found to be specific to the OF test, as the time spent in the open arms of the EPM (another index of anxiety) was not significantly affected by MPD treatment in this study. Nevertheless, a nonsignificant tendency toward a decrease in this behavior could be seen in MPD-treated animals. We have previously demonstrated that some drugs that have anxiolytic effects on the OF may not have the same effect on the EPM and vice versa (Vendruscolo et al., 2003) . Thus, it is likely that the different tests used may assess partially distinct types of emotionality (Ramos and Mormède, 1998) . Therefore, the significant effects of MPD that were shown to depend, in this study, on the behavioral test used are likely to result from the different types of stressful experience that the EPM and the OF tests may evoke in the animals. Accordingly, the present findings support recent reports of increased anxious-like behaviors in adult rats induced by early developmental exposure to MPD (Bolaños et al., 2003; Britton et al., 2007) .
The anxious-like behavior in MPD-treated females observed herein was accompanied by an enhanced ethanol intake. The lack of significant effect on the preference for ethanol, however, indicates that the MPD effect on ethanol drinking was moderate. In contrast, the absence of differences in the consumption of saccharine and quinine suggests that the increased ethanol intake observed in the MPD-treated group, although moderate, results from changes in the sensitivity of rats to the pharmacological effects of ethanol rather than changes in their taste preferences. These results add to the body of evidence suggesting that early exposure to MPD makes the reward system more sensitive to appetitive stimuli (Brandon et al., 2001; Schenk and Izenwasser, 2002; Yang et al., 2003; Torres-Reveron and Dow-Edwards, 2005; Crawford et al., 2007) . Interestingly, it has been estimated that almost 50% of the ADHD cases in adults also meet criteria for one or more anxiety disorders, with a higher prevalence in females than in males, and more than 25% of adults with ADHD have alcohol/drug dependence (Biederman, 2005; Wilens et al., 2005) . In addition, higher rates of anxiety disorders also exist in individuals with ADHD and alcohol/drug addiction as compared to individuals with ADHD only, alcohol/drug dependence only or the control group (Wilens et al., 2005) . These results indicate the possibility that chronic MPD treatment in children or adolescents may lead to ADHD adults with cooccurring anxiety disorders and/or alcoholism. This hypothesis remains to be tested. Two-choice ethanol (10%, v/v) versus water intake (upper panel) and preference (bottom panel) of male (M) and female (F) SHRs treated during pre/periadolescence (PD23-38) with MPD (2 mg/kg intraperitoneally, twice daily for 16 consecutive days) or SAL. All animals were given a choice between ethanol 10% (v/v) and water over 20 days (10 two-day blocks). Data on ethanol intake are expressed as gram of absolute ethanol consumed daily per kilogram body weight (g/kg/day). Curves and vertical lines represent the means and SEM of animals grouped by sex and treatment; n = 10-12 per group. # P < 0.05 for difference between MPD-treated and SAL-treated female rats across 2-day blocks; + + P < 0.01 for effect of sex. MPD, methylphenidate; PD, postnatal day; SHRs, spontaneously hypertensive rats.
Methylphenidate induces anxiety and ethanol intake Vendruscolo et al. 25 In childhood and adolescence the individual is more vulnerable to external insults (see, for review, Andersen, 2003; Adriani and Laviola, 2004; Crews et al., 2007) . Considering that repeated exposure to MPD, like other psychostimulants, can induce long-lasting molecular and cellular changes (Andersen et al., 2002; Yang et al., 2003; Torres-Reveron and Dow-Edwards, 2005; Adriani et al., 2006; Grund et al., 2006; Hyman et al., 2006) in brain dopaminergic structures, one could hypothesize that alterations in the mesolimbic DA system are involved in the persistent MPD effects observed in this study. In this regard, the role of DA in emotionality and reward has been demonstrated in both rodents (Pfeffer and Samson, 1988; Rogerio and Takahashi, 1992; Blanchard and Blanchard, 1999) and humans (Tupala and Tiihonen, 2004; Denys et al., 2006) . Certainly, additional studies are necessary to better understand the cellular and molecular alterations caused by MPD in SHRs as well as in other models of ADHD.
Although ADHD affects both men and women (Biederman et al., 1994) , the vast majority of the animal studies investigating this issue have been performed with male animals. The biological mechanisms underlying hormonal influences on behavior and pharmacological sensitivity are complex and not fully understood. Both organizational and activational influences of gonadal hormones could be involved (Kuhn et al., 2001) . For example, ChatterjeeChakrabarty et al. (2005) have reported that developmental exposure to MPD disturbs hormonal function in periadolescent female rats. Moreover, neurobiological mechanisms, independent of hormonal action, may trigger sexual differentiation of brain and behavior (Arnold, 1996) . Given that different brain structures (linked to different functions) do not necessarily mature at the same developmental periods and that males and females have different periods of brain maturation (Andersen and Teicher, 2000; Andersen, 2005; Crews et al., 2007) , it is possible that the sex differences observed in this study are due to distinct influences of MPD on the brain development of each sex. At the same time, sex differences in the sensitivity to psychostimulants, drug metabolism and bioavailability (e.g. Kuhn et al., 2001) should not be overlooked. Further studies are needed to investigate the specific effect of MPD on female behavior as well as sex differences in the effects of MPD. Finally, in this study, female rats showed fewer anxiety-like behaviors, higher locomotion and higher saccharine and ethanol intake than males, which confirms earlier studies (e.g. Vendruscolo et al., 2006) .
In conclusion, the results of this study show that early developmental exposure to MPD in SHRs enhances a specific anxiety-like behavior and ethanol intake (the latter only in females) when animals are tested in adulthood. These findings suggest that besides the clinically useful effects of MPD, its persistent adverse effects could contribute, at least in part, to the high rates of psychiatric comorbidity (e.g. anxiety disorder and alcoholism) observed in ADHD patients. Gaining an understanding of the molecular and behavioral alterations produced by chronic MPD treatment during development is a crucial step toward the development of therapies with fewer adverse effects while preserving the useful properties of the drug.
